vimarsana.com

Page 2 - Source Ucb Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

/PRNewswire/ UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis.

Bruxelles capitaleDaphne teoCharl van zylJim baxterIris loew friedrichAntje witteLaurent schotsNeurology head of europe internationalUs communicationsAmerican association of neuromuscular electrodiagnostic medicineBrand communicationsEuropean commissionDrug administrationCorporate communicationsEuropean unionMyasthenia gravis foundation of america

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United kingdomBruxelles capitaleGreat britainNicole hergaD vidal sarroEmmanuel caeymaexN nunez gomezM concetta fargnoliB wilson clarAntje witteImmunology solutionsEuropean academy of dermatologyDrug administrationGroup of companiesEuropean union eu economic areaUs immunology communications

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Through collaborations with Le Bonheur Children s Hospital, the Wisconsin Health Information Organization, and Yale University, UCB seeks to further understand.

United statesBruxelles capitaleErica puntelBrad chapmanGeorge morrisJames whelessAntje witteGlobal communicationsCenters for diseaseYale universityNeuroscience instituteEpilepsy foundation of americaUs communicationsWisconsin health information organizationSource ucb incRare syndromes

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

Press release content from PR Newswire. The AP news staff was not involved in its creation.

United statesBruxelles capitaleEmmanuel caeymaexEimear obrienAntje witteImmunology solutionsEuropean congressBrand communicationsUcb incDrug administrationAssessment of spondyloarthritis international societyCorporate communicationsSource ucb incExecutive vice presidentSpondyloarthritis international societyEuronext brussels

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

/PRNewswire/ UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating.

United statesUnited kingdomBruxelles capitaleEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsEuropean congressBrand communicationsUcb incDrug administrationAssessment of spondyloarthritis international societyCorporate communicationsSource ucb inc

vimarsana © 2020. All Rights Reserved.